To this end, three pancreatic cancer cell lines derived from a genetically engineered doxycycline-inducible KrasG12D transgenic mouse model: 4292 i-Kras, 4668 i-Kras, and 9805 i-Kras cells (Collins et al, 2012; Mathison et al, 2021) were utilized. The gene discussed is KRAS; the disease is pancreatic neoplasm.